
Remibrutinib (LOU064) versus placebo in CSU patients: Study design of the two Phase 3 clinical trials, REMIX-I and REMIX-II
M. Maurer, A. Giménez-Arnau, S. Saini, M. Lebwohl, G. Sussman, M. Hide, K. Lheritier, A. Zharkov, A. Barron, K. Cook, E-D. Martzloff, S. Haemmerle